A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

• Status: Not yet recruiting
• Trial end date: 2023-01-02
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of tocilizumab (TCZ) for the treatment of pediatric patients from birth to less than 18 years old hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche

Criteria

Inclusion Criteria:

• Hospitalized with COVID-19 confirmed per a positive PCR of any specimen (e.g., respiratory, blood, urine, stool, or other bodily fluid) and evidenced by chest x-ray or CT scan

• Receiving systemic corticosteroids at baseline

• Oxygen saturation < 93% on room air, or requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) to maintain oxygen saturation > 92% at screening and baseline

Exclusion Criteria:

• Gestational age < 37 weeks

• Known severe allergic reactions to TCZ or other monoclonal antibodies

• Active tuberculosis infection

• Uncontrolled active bacterial, fungal, viral, or other infection (besides COVID-19)

• Diagnosis or suspected diagnosis of multisystem inflammatory syndrome in children (MIS-C)

• In the opinion of the investigator, progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatments

• Have received oral anti-rejection or immunomodulatory drugs (including TCZ) within the past 3 months prior to enrollment

• Treatment with an investigational drug within 5 drug-elimination half-lives or 30 days, whichever is longer, of enrollment (except for anti-SARS-CoV-2 antibodies or directly-acting antivirals)

• Participating in another interventional drug clinical trial (except for anti-SARS-CoV-2 antibodies or directly-acting antivirals)